SCHEMBL24706386

SCHEMBL24706386

CCOc1ccc2nc(NN=C(C#N)C#N)sc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.56
▸ SMN1; SMN2 Q16637 8/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ HPGD P15428 4/20 0.56
▸ HSD17B10 Q99714 3/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ NPC1 O15118 9/20 0.56
▸ RAB9A P51151 9/20 0.56
▸ KMT2A Q03164 6/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ TDP1 Q9NUW8 3/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.56
▸ NFKB1 P19838 2/20 0.56
▸ NFKB2 Q00653 2/20 0.56
▸ RELA Q04206 2/20 0.56
▸ APOBEC3G Q9HC16 1/20 0.56
▸ TP53 P04637 5/20 0.55
▸ POLB P06746 2/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ HTT P42858 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923102 0.87 NPC1 (0.56) MAPTSMN1; SMN2ALDH1A1HPGDL3MBTL1
SCHEMBL24705956 0.81 DYRK1A (0.58) MAPTSMN1; SMN2ALDH1A1HSD17B10NPC1
SCHEMBL24707371 0.81 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1HPGDL3MBTL1
SCHEMBL24705959 0.80 DYRK1A (0.53) MAPTSMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL11191318 0.78 KMT2A (0.73) MAPTSMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL24707315 0.78 SMN1; SMN2 (0.55) MAPTSMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL24707000 0.78 MAPT (0.55) MAPTSMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL24706384 0.78 RAB9A (0.52) MAPTALDH1A1HPGDNPC1RAB9A
SCHEMBL2076821 0.76 SMN1; SMN2 (0.67) MAPTSMN1; SMN2ALDH1A1HPGDHSD17B10
SCHEMBL24706983 0.75 GAA (0.44) MAPTSMN1; SMN2ALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT MAPT 3061/4885SMN1; SMN2 4864/4885ALDH1A1 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback